Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis

References

• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;375:1303. doi:10.1056/NEJMc1609622
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783. doi:10.1136/ard.2009.108233
   PubMed Web of Science ®Google Scholar
• Tournadre A, Pereira B, Lhoste A, et al. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res. 2013;65:1482–1489. doi:10.1002/acr.22001
   PubMed Web of Science ®Google Scholar
• Akkoc N, Khan MA. ASAS classification criteria for axial spondyloarthritis: time to modify. Clin Rheumatol. 2016;35:1415–1423. doi:10.1007/s10067-016-3261-6
   PubMed Web of Science ®Google Scholar
• Slobodin G, Eshed I. Non-radiographic axial spondyloarthritis. Isr Med Assoc J. 2015;17:770–776.
   Web of Science ®Google Scholar
• Wallman JK, Kapetanovic MC, Petersson IF, et al. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients–baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Res Ther. 2015;17:378. doi:10.1186/s13075-015-0897-6
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, Reveille JD, et al. Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain. Arthritis Rheumatol. 2016;68:1669–1676. doi:10.1002/art.39612
   PubMed Web of Science ®Google Scholar
• Rouvier E, Luciani MF, Mattéi MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150:5445–5456.
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951–1957. doi:10.1084/jem.20030896
   PubMed Web of Science ®Google Scholar
• Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11:562. doi:10.1038/nrrheum.2015.128
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517. doi:10.1146/annurev.immunol.021908.132710
   PubMed Web of Science ®Google Scholar
• Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155:5483–5486.
   PubMed Web of Science ®Google Scholar
• Kao CY, Huang F, Chen Y, et al. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol. 2005;175:6676–6685. doi:10.4049/jimmunol.175.10.6676
   PubMed Web of Science ®Google Scholar
• Shahrara S, Pickens SR, Mandelin AM, et al. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol. 2010;184:4479–4487. doi:10.4049/jimmunol.0901942
   PubMed Web of Science ®Google Scholar
• Hartupee J, Liu C, Novotny M, et al. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol. 2007;179:4135–4141. doi:10.4049/jimmunol.179.6.4135
   PubMed Web of Science ®Google Scholar
• Schwarzenberger P, La Russa V, Miller A, et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol. 1998;161:6383–6389.
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271–2279. doi:10.1084/jem.20061308
   PubMed Web of Science ®Google Scholar
• Taams LS, Steel KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453–466. doi:10.1038/s41584-018-0044-2
   PubMed Web of Science ®Google Scholar
• Chabaud M, Garnero P, Dayer JM, et al. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000;12:1092–1099. doi:10.1006/cyto.2000.0681
   PubMed Web of Science ®Google Scholar
• Koenders MI, Kolls JK, Oppers-Walgreen B, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 2005;52:3239–3247. doi:10.1002/art.21342
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345–1352. doi:10.1172/JCI5703
   PubMed Web of Science ®Google Scholar
• Pickens SR, Volin MV, Mandelin AM, et al. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 2010;184:3233–3241. doi:10.4049/jimmunol.0903271
   PubMed Web of Science ®Google Scholar
• Gullick NJ, Evans HG, Church LD, et al. Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One. 2010;5:e12516. doi:10.1371/journal.pone.0012516
   Web of Science ®Google Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17:435–440. doi:10.1038/cr.2007.35
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205:1063–1075. doi:10.1084/jem.20071978
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Adachi M, Oda N, et al. IL-17 cytokine family. J Allergy Clin Immunol. 2004;114:1265–1273. doi:10.1016/j.jaci.2004.10.019
   PubMed Web of Science ®Google Scholar
• Sorbello V, Ciprandi G, Di Stefano A, et al. Nasal IL-17F is related to bronchial IL-17F/neutrophilia and exacerbations in stable atopic severe asthma. Allergy. 2015;70:236–240. doi:10.1111/all.12547
   PubMed Web of Science ®Google Scholar
• Billingham ME. Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther. 1983;21:389–428. doi:10.1016/0163-7258(83)90062-1
   PubMed Web of Science ®Google Scholar
• Bush KA, Farmer KM, Walker JS, et al. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002;46:802–805. doi:10.1002/art.10173
   PubMed Web of Science ®Google Scholar
• Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171:6173–6177. doi:10.4049/jimmunol.171.11.6173
   PubMed Web of Science ®Google Scholar
• Corneth OB, Mus AM, Asmawidjaja PS, et al. Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol. 2014;66:340–349. doi:10.1002/art.38229
   Web of Science ®Google Scholar
• Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7:29–37. doi:10.1186/ar1478
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LA, van de Loo FA, et al. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res. 2002;51:102–104. doi:10.1007/BF02684010
   PubMed Web of Science ®Google Scholar
• Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, et al. Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol. 2015;67:2813–2827. doi:10.1002/art.39282
   PubMed Web of Science ®Google Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–2643. doi:10.1002/art.24763
   PubMed Web of Science ®Google Scholar
• Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64:110–120. doi:10.1002/art.33321
   PubMed Web of Science ®Google Scholar
• Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426:454–460. doi:10.1038/nature02119
   PubMed Web of Science ®Google Scholar
• Ruutu M, Thomas G, Steck R, et al. β-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum. 2012;64:2211–2222. doi:10.1002/art.34423
   PubMed Web of Science ®Google Scholar
• Benham H, Rehaume LM, Hasnain SZ, et al. Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66:1755–1767. doi:10.1002/art.38638
   PubMed Web of Science ®Google Scholar
• Gillet P, Bannwarth B, Charrière G, et al. Studies on type II collagen induced arthritis in rats: an experimental model of peripheral and axial ossifying enthesopathy. J Rheumatol. 1989;16:721–728.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–1076. doi:10.1038/nm.2817
   PubMed Web of Science ®Google Scholar
• Ebihara S, Date F, Dong Y, et al. Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity. 2015;48:259–266. doi:10.3109/08916934.2014.976630
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz JP, Racadot E, et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74:304–305. doi:10.1016/j.jbspin.2006.11.005
   PubMed Web of Science ®Google Scholar
• Romero-Sanchez C, Jaimes DA, Londoño J, et al. Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. Clin Exp Rheumatol. 2011;29:828–834.
   Web of Science ®Google Scholar
• Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc. 2012;75:303–308. doi:10.1016/j.jcma.2012.05.006
   PubMed Web of Science ®Google Scholar
• Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol. 2013;33:151–161. doi:10.1007/s10875-012-9774-0
   PubMed Web of Science ®Google Scholar
• Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62:2876–2885. doi:10.1002/art.27622
   PubMed Web of Science ®Google Scholar
• Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol. 2007;34:2285–2290.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419–429. doi:10.1007/s11010-011-1036-6
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60:955–965. doi:10.1002/art.24389
   PubMed Web of Science ®Google Scholar
• van Baarsen LG, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16:426. doi:10.1186/s13075-014-0426-z
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–532. doi:10.1136/annrheumdis-2017-212127
   PubMed Web of Science ®Google Scholar
• Zrioual S, Ecochard R, Tournadre A, et al. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009;182:3112–3120. doi:10.4049/jimmunol.0801967
   PubMed Web of Science ®Google Scholar
• Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183:2593–2603. doi:10.1084/jem.183.6.2593
   PubMed Web of Science ®Google Scholar
• Zrioual S, Toh ML, Tournadre A, et al. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol. 2008;180:655–663. doi:10.4049/jimmunol.180.1.655
   Web of Science ®Google Scholar
• Chabaud M, Fossiez F, Taupin JL, et al. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol. 1998;161:409–414.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Iwamoto N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol. 2009;36:2397–2402. doi:10.3899/jrheum.090132
   PubMed Web of Science ®Google Scholar
• Teunissen MB, Koomen CW, de Waal Malefyt R, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645–649. doi:10.1046/j.1523-1747.1998.00347.x
   PubMed Web of Science ®Google Scholar
• Wedebye Schmidt EG, Larsen HL, Kristensen NN, et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis. 2013;19:1567–1576. doi:10.1097/MIB.0b013e318286fa1c
   PubMed Web of Science ®Google Scholar
• Henness S, van Thoor E, Ge Q, et al. IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. Am J Physiol Lung Cell Mol Physiol. 2006;290:L1283–1290. doi:10.1152/ajplung.00367.2005
   PubMed Web of Science ®Google Scholar
• Friday SC, Fox DA. Phospholipase D enzymes facilitate IL-17- and TNFα-induced expression of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASF). Immunol Lett. 2016;174:9–18. doi:10.1016/j.imlet.2016.04.001
   Web of Science ®Google Scholar
• Srenathan U, Steel K, Taams LS. IL-17+ CD8+ T cells: differentiation, phenotype and role in inflammatory disease. Immunol Lett. 2016;178:20–26. doi:10.1016/j.imlet.2016.05.001
   PubMed Web of Science ®Google Scholar
• Papotto PH, Ribot JC, Silva-Santos B. IL-17+ γδ T cells as kick-starters of inflammation. Nat Immunol. 2017;18:604–611. doi:10.1038/ni.3726
   PubMed Web of Science ®Google Scholar
• Hazenberg MD, Spits H. Human innate lymphoid cells. Blood. 2014;124:700–709. doi:10.1182/blood-2013-11-427781
   PubMed Web of Science ®Google Scholar
• Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66:1272–1281. doi:10.1002/art.38376
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146–155. doi:10.2353/ajpath.2008.070690
   PubMed Web of Science ®Google Scholar
• Ortega C, Fernández-A S, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86:435–443. doi:10.1189/JLB.0109046
   PubMed Web of Science ®Google Scholar
• Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108. doi:10.1371/journal.pone.0014108
   PubMed Web of Science ®Google Scholar
• Hijnen D, Knol EF, Gent YY, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. J Invest Dermatol. 2013;133:973–979. doi:10.1038/jid.2012.456
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Villanova F, Navarini AA, et al. Targeting CD8(+) T cells prevents psoriasis development. J Allergy Clin Immunol. 2016;138:274–276.e276. doi:10.1016/j.jaci.2015.10.046
   PubMed Web of Science ®Google Scholar
• Wang C, Liao Q, Hu Y, et al. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med. 2015;9:250–256. doi:10.3892/etm.2014.2046
   PubMed Web of Science ®Google Scholar
• Al-Mossawi MH, Chen L, Fang H, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017;8:1510. doi:10.1038/s41467-017-01771-2
   PubMed Web of Science ®Google Scholar
• Steel KWS, Srenathan U, Chan E, Kirkham BW, Taams LS. 0016 Synovial IL-17+CD8+ T cells are a pro-inflammatory tissue resident population enriched in spondyloarthritis. Ann Rheum Dis. 2018;77:A8–A9.
   Web of Science ®Google Scholar
• Cheuk S, Schlums H, Gallais Sérézal I, et al. CD49a expression defines tissue-resident CD8 + T cells poised for cytotoxic function in human skin. Immunity. 2017;46:287–300. doi:10.1016/j.immuni.2017.01.009
   PubMed Web of Science ®Google Scholar
• Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192:3111–3120. doi:10.4049/jimmunol.1302313
   PubMed Web of Science ®Google Scholar
• Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006;176:4431–4439. doi:10.4049/jimmunol.176.7.4431
   PubMed Web of Science ®Google Scholar
• Watanabe R, Gehad A, Yang C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7:279ra239. doi:10.1126/scitranslmed.3010302
   Web of Science ®Google Scholar
• Laggner U, Di Meglio P, Perera GK, et al. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol. 2011;187:2783–2793. doi:10.4049/jimmunol.1100804
   PubMed Web of Science ®Google Scholar
• Petrelli A, van Wijk F. CD8(+) T cells in human autoimmune arthritis: the unusual suspects. Nat Rev Rheumatol. 2016;12:421–428. doi:10.1038/nrrheum.2016.74
   Web of Science ®Google Scholar
• Dusseaux M, Martin E, Serriari N, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood. 2011;117:1250–1259. doi:10.1182/blood-2010-08-303339
   PubMed Web of Science ®Google Scholar
• Teunissen MBM, Yeremenko NG, Baeten DLP, et al. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol. 2014;134:2898–2907. doi:10.1038/jid.2014.261
   PubMed Web of Science ®Google Scholar
• Hayashi E, Chiba A, Tada K, et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. J Rheumatol. 2016;43:1695–1703. doi:10.3899/jrheum.151133
   PubMed Web of Science ®Google Scholar
• Gracey E, Qaiyum Z, Almaghlouth I, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124–2132. doi:10.1136/annrheumdis-2015-208902
   PubMed Web of Science ®Google Scholar
• Yoshiga Y, Goto D, Segawa S, et al. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med. 2008;22:369–374.
   PubMed Web of Science ®Google Scholar
• Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420–1429. doi:10.1002/art.33507
   PubMed Web of Science ®Google Scholar
• Gaur P, Misra R, Aggarwal A. Natural killer cell and gamma delta T cell alterations in enthesitis related arthritis category of juvenile idiopathic arthritis. Clin Immunol. 2015;161:163–169. doi:10.1016/j.clim.2015.07.012
   Web of Science ®Google Scholar
• Guggino G, Ciccia F, Di Liberto D, et al. Interleukin (IL)-9/IL-9R axis drives γδ T cells activation in psoriatic arthritis patients. Clin Exp Immunol. 2016;186:277–283. doi:10.1111/cei.12853
   PubMed Web of Science ®Google Scholar
• Chowdhury AC, Chaurasia S, Mishra SK, et al. IL-17 and IFN-γ producing NK and γδ-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis. Clin Immunol. 2017;183:207–212. doi:10.1016/j.clim.2017.03.016
   Web of Science ®Google Scholar
• Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity. 2011;35:596–610. doi:10.1016/j.immuni.2011.08.001
   PubMed Web of Science ®Google Scholar
• Gray EE, Suzuki K, Cyster JG. Cutting edge: identification of a motile IL-17-producing gammadelta T cell population in the dermis. J Immunol. 2011;186:6091–6095. doi:10.4049/jimmunol.1100427
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Ebsworth K, Ertl LS, et al. IL-17-secreting γδ T cells are completely dependent upon CCR6 for homing to inflamed skin. J Immunol. 2017;199:3129–3136. doi:10.4049/jimmunol.1700826
   Web of Science ®Google Scholar
• Reinhardt A, Yevsa T, Worbs T, et al. Interleukin-23-dependent γ/δ T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol. 2016;68:2476–2486. doi:10.1002/art.39732
   PubMed Web of Science ®Google Scholar
• Soare A, Weber S, Maul L, et al. Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. J Immunol. 2018;200:1249–1254. doi:10.4049/jimmunol.1700596
   Web of Science ®Google Scholar
• Leijten EFA, van Kempen TS, Boes M, et al. Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol. 2015;67(10):2673–2678. doi:10.1002/art.39261
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64:99–109. doi:10.1002/art.33396
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Blijdorp I, Chen S, et al. Human mast cells capture, store, and release bioactive, exogenous IL-17A. J Leukoc Biol. 2016;100:453–462. doi:10.1189/jlb.3HI1215-542R
   PubMed Web of Science ®Google Scholar
• Wendling D, Verhoeven F, Prati C. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2019;19:55–64. doi:10.1080/14712598.2019.1554053
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991. doi:10.1136/annrheumdis-2016-210770
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71:1599–1613. doi:10.1002/art.41042
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2016;16:711–722. doi:10.1517/14712598.2016.1167183
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–1713. doi:10.1016/S0140-6736(13)61134-4
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548. doi:10.1056/NEJMoa1505066
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76:571–592. doi:10.1136/annrheumdis-2016-210023
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Taniguchi A, Fujishige A, et al. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label Phase 3 study (MEASURE 2-J). Mod Rheumatol. 2020;30:132–140. doi:10.1080/14397595.2018.1538004
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19:285. doi:10.1186/s13075-017-1490-y
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5:447–462. doi:10.1007/s40744-018-0123-5
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76:1070–1077. doi:10.1136/annrheumdis-2016-209730
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Carriero A, Gilio M, et al. Safety of treatment options for spondyloarthritis: a narrative review. Expert Opin Drug Saf. 2018;17:475–486. doi:10.1080/14740338.2018.1448785
   PubMed Web of Science ®Google Scholar
• Torgutalp M, Poddubnyy D. IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin Biol Ther. 2019;19:631–641. doi:10.1080/14712598.2019.1605352
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5:e001005. doi:10.1136/rmdopen-2019-001005
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz AJ, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2:e339–e346. doi:10.1016/S2665-9913(20)30066-7
   Google Scholar
• Baraliakos X, Van den Bosch F, Machado PM, et al. Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2020. doi:10.1007/s40744-020-00269-6
   Web of Science ®Google Scholar
• Dubash S, Bridgewood C, McGonagle D, et al. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol. 2019;15:123–134. doi:10.1080/1744666X.2019.1561281
   PubMed Web of Science ®Google Scholar
• Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–120. doi:10.1002/art.41477
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang S, Hu B, et al. Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2021. doi:10.1007/s10067-020-05545-y
   Web of Science ®Google Scholar
• Gentileschi S, Vitale A, Rigante D, et al. Prompt clinical response to secukinumab in patients with axial spondyloarthritis: real life observational data from three italian referral centers. Isr Med Assoc J. 2018;20:438–441.
   PubMed Web of Science ®Google Scholar
• Gentileschi S, Rigante D, Sota J, et al. Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediators Inflamm. 2020;2020:6983272. doi:10.1155/2020/6983272
   PubMed Web of Science ®Google Scholar
• Mann HF, Závada J, Šenolt L, et al. Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clin Exp Rheumatol. 2019;37:342–343.
   PubMed Web of Science ®Google Scholar
• Elliott A, Wright G. Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19858510. doi:10.1177/1759720X19858510
   PubMed Web of Science ®Google Scholar
• Williams T, Wadeley A, Bond D, et al. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath. Clin Rheumatol. 2020;39:1501–1504. doi:10.1007/s10067-020-04944-5
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Fonti GL, Conigliaro P, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20:813–821. doi:10.1080/14712598.2020.1761957
   PubMed Web of Science ®Google Scholar
• Michelsen B, Lindström U, Codreanu C, et al. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open. 2020;6(3):e001280. doi:10.1136/rmdopen-2020-001280
   PubMedGoogle Scholar
• Yu CL, Yang CH, Chi CC. Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence. BioDrugs. 2020;34:669–679. doi:10.1007/s40259-020-00442-x
   Web of Science ®Google Scholar
• Goeree R, Chiva-Razavi S, Gunda P, et al. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. J Med Econ. 2019;22:45–52. doi:10.1080/13696998.2018.1539400
   PubMed Web of Science ®Google Scholar
• Purmonen T, Puolakka K, Mishra D, et al. Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. Clinicoecon Outcomes Res. 2019;11:159–168. doi:10.2147/CEOR.S192235
   PubMed Web of Science ®Google Scholar
• Emery P, Van Keep M, Beard S, et al. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018;36:1015–1027. doi:10.1007/s40273-018-0675-9
   PubMed Web of Science ®Google Scholar
• Kiltz U, Sfikakis PP, Gaffney K, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther. 2020;37:2865–2883. doi:10.1007/s12325-020-01352-8
   PubMed Web of Science ®Google Scholar
• Micheroli R, Tellenbach C, Scherer A, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2020;79:1203–1209. doi:10.1136/annrheumdis-2019-215934
   PubMed Web of Science ®Google Scholar
• Glintborg B, Lindstrom U, Di Giuseppe D, et al. One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis. Arthritis Care Res. 2020. doi:10.1002/acr.24523
   Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441–2451. doi:10.1016/S0140-6736(18)31946-9
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71:599–611. doi:10.1002/art.40753
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021;372:m4447. doi:10.1136/bmj.m4447
   PubMed Web of Science ®Google Scholar
• Rademacher J, Poddubnyy D. Emerging drugs for the treatment of axial spondyloarthritis. Expert Opin Emerg Drugs. 2018;23:83–96. doi:10.1080/14728214.2018.1445719
   PubMed Web of Science ®Google Scholar
• Dougados M, Wei JC, Landewé R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79:176–185. doi:10.1136/annrheumdis-2019-216118
   PubMed Web of Science ®Google Scholar
• Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395:53–64. doi:10.1016/S0140-6736(19)32971-X
   PubMed Web of Science ®Google Scholar
• Kiwalkar S, Beier S, Deodhar A. Ixekizumab for treating ankylosing spondylitis. Immunotherapy. 2019;11:1273–1282. doi:10.2217/imt-2019-0094
   Web of Science ®Google Scholar
• San Koo B, Kim TH. The role of ixekizumab in non-radiographic axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X20986734. doi:10.1177/1759720X20986734
   Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473–479. doi:10.1136/annrheumdis-2018-214273
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189. doi:10.1056/NEJMoa1109017
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78:81–89.e85. doi:10.1016/j.jaad.2017.08.024
   PubMed Web of Science ®Google Scholar
• Wei JCC, Kim TH, Kishimoto M, et al. OP0234 efficacy and safety of brodalumab, an anti-interleukin-17 receptor a monoclonal antibody, in patients with axial spondyloarthritis: a 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study. Ann Rheum Dis. 2019;78:195. doi:10.1136/annrheumdis-2019-eular.6888
   Web of Science ®Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79:595–604. doi:10.1136/annrheumdis-2020-216980
   PubMed Web of Science ®Google Scholar
• Erdes S, Nasonov E, Kunder E, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020;38:27–34.
   PubMed Web of Science ®Google Scholar